Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Edesa Biotech (EDSA) EBIT (2016 - 2022)

Edesa Biotech's EBIT history spans 10 years, with the latest figure at -$2.8 million for Q3 2022.

  • For Q3 2022, EBIT rose 48.29% year-over-year to -$2.8 million; the TTM value through Sep 2022 reached -$18.4 million, up 22.43%, while the annual FY2025 figure was -$1.9 million, 72.77% up from the prior year.
  • EBIT for Q3 2022 was -$2.8 million at Edesa Biotech, up from -$5.8 million in the prior quarter.
  • Across five years, EBIT topped out at -$405741.0 in Q4 2018 and bottomed at -$9.5 million in Q1 2021.
  • The 5-year median for EBIT is -$2.2 million (2020), against an average of -$3.1 million.
  • The largest annual shift saw EBIT soared 70.81% in 2018 before it crashed 527.23% in 2021.
  • A 5-year view of EBIT shows it stood at -$405741.0 in 2018, then tumbled by 172.51% to -$1.1 million in 2019, then crashed by 136.4% to -$2.6 million in 2020, then crashed by 97.48% to -$5.2 million in 2021, then skyrocketed by 45.05% to -$2.8 million in 2022.
  • Per Business Quant, the three most recent readings for EDSA's EBIT are -$2.8 million (Q3 2022), -$5.8 million (Q2 2022), and -$4.6 million (Q1 2022).